C017 Dermatology Review: Skin Cancer, Surgical, and Cosmetic
DESCRIPTION
Tuition fee and ticket required for admission
In the surgical portion of this course, we will analyze the value added in the designation of a chronic disease for the treatment of the patient population with multiple keratinocyte carcinomas, develop an approach to the use of chemoprophylaxis in patients with multiple squamous cell carcinomas, describe the evidence for Mohs for melanoma and summarize the surgical management of dysplastic nevi and AIMP.
In the cosmetic portion of this course, we will discuss new laser and energy devices; evaluate and compare neuromodulators currently available on the market, outline an approach to the treatment of rhinophyma, and learn how to best utilize injectables as biostimulators.
Finally, we will end with a roundtable discussion-based format on optimizing models for the use of mid-levels in dermatologic practice.
LEARNING OBJECTIVES
Analyze the value added in the designation of a chronic disease for the treatment of the patient population with multiple keratinocyte carcinomas; develop an approach to the use of chemoprophylaxis in patients with multiple squamous cell carcinomas; describe the evidence for Mohs for melanoma; summarize the surgical management of dysplastic nevi and AIMP.
Discuss new laser and energy devices; evaluate and compare neuromodulators currently available on the market, outline an approach to the treatment of rhinophyma, and learn how to best utilize injectables as biostimulators.
Discuss optimal models for the use of mid-levels in practice.
SCHEDULE
8:00 PM
Surgical management of dysplastic nevi and AIMP
Natalie Spaccarelli, MD
8:15 PM
Value added in consideration of NMSC as chronic disease
Adam Vincent Sutton, MD, MBA, FAAD
8:30 PM
When to use chemoprophylaxis in patients with multiple SCC
Joi B. Carter, MD, FAAD
8:45 PM
Update: The evidence for Mohs for melanoma
Naomi Lawrence, MD, FAAD
9:00 PM
Discussion
Naomi Lawrence, MD, FAAD, Joi B. Carter, MD, FAAD, Natalie Spaccarelli, MD, Adam Vincent Sutton, MD, MBA, FAAD
9:07 PM
Use of filler as a biostimulator
Kimberly J. Butterwick, MD, FAAD
9:22 PM
What is new in laser and energy based devices?"
Omar Ibrahimi, MD, PhD, FAAD
9:37 PM
Comparison of Toxins available and rationale for using different toxins
Deirdre Hooper, MD, FAAD
9:52 PM
Update on the treatment of Rhinophyma
Suzanne L Kilmer, MD, FAAD
10:07 PM
Discussion
Kimberly J. Butterwick, MD, FAAD, Deirdre Hooper, MD, FAAD, Omar Ibrahimi, MD, PhD, FAAD, Suzanne L Kilmer, MD, FAAD
10:15 PM
Optimizing the model for use of midlevel providers
Allison Therese Vidimos, MD, RPh, FAAD
10:30 PM
Optimizing the model for use of midlevel providers
Allison K. Arthur, MD, FAAD
10:45 PM
Discussion
Naomi Lawrence, MD, FAAD, Allison K. Arthur, MD, FAAD, Allison Therese Vidimos, MD, RPh, FAAD
SPEAKERS
Allison K. Arthur, MD, FAAD
Kimberly J. Butterwick, MD, FAAD
Joi B. Carter, MD, FAAD
Deirdre Hooper, MD, FAAD
Omar Ibrahimi, MD, PhD, FAAD
Suzanne L Kilmer, MD, FAAD
Naomi Lawrence, MD, FAAD
Natalie Spaccarelli, MD
Adam Vincent Sutton, MD, MBA, FAAD
Allison Therese Vidimos, MD, RPh, FAAD
SPEAKER DISCLOSURES
Allison K. Arthur, MD, FAAD
Sand Lake Dermatology Center – Other(Salary); Society of Dermatology Physician Assistants – Speaker(Honoraria);
Kimberly J. Butterwick, MD, FAAD
Allergan, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Evolus, Inc. – Advisory Board(Honoraria); Galderma Laboratories, L.P. – Advisory Board(Honoraria); Merz Pharmaceuticals, LLC – Advisory Board(Honoraria); Revance Therapeutics, Inc. – Advisory Board(Honoraria); Suneva Medical, Inc. – Advisory Board(Honoraria);
Joi B. Carter, MD, FAAD
No financial relationships exist with ineligible companies.
Deirdre Hooper, MD, FAAD
AbbVie – Investigator(Fees), Investigator(Honoraria); Affibody – Investigator(Fees), Investigator(Honoraria); Alfasigma Global – Investigator(Fees), Investigator(Honoraria); Allergan, Inc – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Honoraria), Speaker(Honoraria); Almirall – Investigator(Fees), Investigator(Honoraria); AnaptysBio – Investigator(Fees), Investigator(Honoraria); Arcutis, Inc. – Investigator(Fees), Investigator(Honoraria); Bellus Health – Investigator(Fees), Investigator(Honoraria); Cara Therapeutics – Investigator(Fees), Investigator(Honoraria); Castle Biosciences – Advisory Board(Honoraria); Dermavant Sciences – Investigator(Honoraria); Dermavant Sciences, Inc. – Investigator(Fees); Evolus, Inc. – Advisory Board(Honoraria); Galderma USA – Investigator(Fees), Investigator(Honoraria), Speaker(Honoraria); Incyte Corporation – Investigator(Fees), Investigator(Honoraria); Mayne Pharma Group – Consultant(Honoraria), Speaker(Honoraria); Pfizer Inc. – Investigator(Fees), Investigator(Honoraria); Revance Therapeutics, Inc. – Advisory Board(Honoraria); Revision Skincare – Advisory Board(Honoraria); RVL Pharmaceuticals – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Investigator(Fees); Supergoop! – Consultant(Honoraria); Taro Pharm – Investigator(Fees), Investigator(Honoraria); Technoderma Medicines – Investigator(Fees), Investigator(Honoraria); Teva Pharmaceuticals USA – Investigator(Fees); TruElastin – Consultant (1099 relationship)(Honoraria); UCB – Investigator(Fees), Investigator(Honoraria); Vichy Laboratoires – Advisory Board(Honoraria); X-Medica – Speaker(Honoraria);
Omar Ibrahimi, MD, PhD, FAAD
AbbVie – Stockholder(Stock); Accure, Inc – Advisory Board(No Compensation Received); Acure Acne – Stockholder(Stock); Allergan, Inc – Advisory Board(Honoraria); AVAVA, LLC – Investigator(Grants/Research Funding), Stockholder(Stock); Beam Therapeutics – Stockholder(Stock); ChromaDex Corp. – Stockholder(Stock); CRISPR Therapeutics – Stockholder(Stock); Cutera, Inc. – Speaker(Honoraria); Cytrellis Biosystems, Inc – Advisory Board(Honoraria); Editas Medicine – Stockholder(Stock); General Electric – Stockholder(Stock); Gingko Bioworks Holding Inc – Stockholder(Stock); Intellia Therapeutics – Stockholder(Stock); Lutronic – Advisory Board(Honoraria); Moderna Therapeutics – Stockholder(Stock); Pfizer Inc. – Stockholder(Stock); Procter & Gamble Company – Stockholder(Stock); Regeneron Pharmaceuticals, Inc. – Stockholder(Stock); Revance Therapeutics, Inc. – Stockholder(Stock); Soltego – Stockholder(Stock); Unilever – Stockholder(Stock); Vertex Pharmaceuticals, Inc. – Stockholder(Stock); Viatris Inc. – Stockholder(Stock);
Suzanne L Kilmer, MD, FAAD
Acclaro Medical – Advisory Board(Grants/Research Funding); Accure Medical, LLC – Stockholder(Stock); Allergan, Inc – Advisory Board(Grants/Research Funding); AVAVA, LLC – Stockholder(No Compensation Received); Avita – Investigator(Grants/Research Funding); Blueberry – Stockholder(Stock); BTL Industries – Advisory Board(Grants/Research Funding); Candescent Partners – Consultant(Honoraria); Cutera, Inc. – Investigator(Grants/Research Funding); Cynosure, Inc. – Investigator(Grants/Research Funding); Cytrellis Biosystems, Inc – Advisory Board(Grants/Research Funding); Dominion Aesthetics – Investigator(Honoraria); Endo Pharmaceuticals – Advisory Board(Grants/Research Funding); Engage Technologies – Stockholder(Stock); Evolus, Inc. – Advisory Board(Honoraria); Galderma USA – Advisory Board(Honoraria); InMode – Investigator(Grants/Research Funding); Lumenis – Investigator(Grants/Research Funding); Lutronics, Inc. – Investigator(Grants/Research Funding); Merz Aesthetics – Investigator(Grants/Research Funding); Miramar Labs – Advisory Board(Honoraria); Pulse Biosciences – Advisory Board(Grants/Research Funding); R2 Dermatology, Inc. – Investigator(Grants/Research Funding); Sciton Inc. – Advisory Board(Grants/Research Funding); Sienna Labs, Inc. – Advisory Board(Honoraria); Sofwave – Consultant(Grants/Research Funding); Solta Medical – Investigator(Grants/Research Funding); Solta Medical Inc – Advisory Board(No Compensation Received); Syneron Candela – Advisory Board(Grants/Research Funding); Venus Concepts – Advisory Board(Grants/Research Funding);
Naomi Lawrence, MD, FAAD
No financial relationships exist with ineligible companies.
Natalie Spaccarelli, MD
No financial relationships exist with ineligible companies.
Adam Vincent Sutton, MD, MBA, FAAD
No financial relationships exist with ineligible companies.
Allison Therese Vidimos, MD, RPh, FAAD
Inhibitor Therapeutics – Advisory Board(No Compensation Received); UpToDate, Inc – Other(Honoraria);